Perioperative Anticoagulation Management for Moderate‑to‑High Bleeding‑Risk Procedures

Warfarin Management

• Stop warfarin 5 days before moderate‑to‑high bleeding‑risk surgery to allow drug clearance (half‑life ≈ 36‑42 h)【1】.
• Measure INR on the day of surgery; postpone the procedure if INR > 1.5【1】.
• For urgent reversal, give low‑dose vitamin K (2.5–5 mg) IV or oral together with fresh‑frozen plasma or prothrombin‑complex concentrate for rapid effect【1】.
• Bridging with therapeutic‑dose LMWH is reserved for patients at highest thrombotic risk (mechanical prosthetic valves, very high‑risk atrial fibrillation, recent venous thromboembolism < 3 months with thrombophilia, or recent biological valve/mitral repair)【1】.
• When bridging is indicated, start LMWH 2 days after warfarin discontinuation (1 day after acenocoumarol)【1】.
• Use therapeutic LMWH dosing of 70 U/kg anti‑Xa twice daily for high‑risk patients【1】.
• Administer the last LMWH dose ≥ 12 h before the procedure【1】.
• Some centers employ IV unfractionated heparin until 4 h before surgery for mechanical valve patients【1】.
• Resume LMWH 1–2 days post‑operatively (≥ 12 h after surgery) according to hemostatic status【1】.
• Restart warfarin on postoperative day 1–2 with the usual maintenance dose plus a 50 % dose boost for two consecutive days【1】.
• Continue LMWH until INR reaches the therapeutic range【1】.

Direct Oral Anticoagulant (DOAC) Management

• Rivaroxaban, apixaban, and edoxaban should be stopped 3 days before moderate‑to‑high bleeding‑risk procedures when creatinine clearance > 30 mL/min【2】.
• For very high hemorrhagic‑risk surgeries (e.g., intracranial or neuraxial procedures), extend interruption up to 5 days【2】.
• Dabigatran interruption depends on renal function:
  
  • CrCl > 50 mL/min: stop 4 days before the procedure.
  • CrCl 30–50 mL/min: stop 5 days before the procedure【2】.
• Age > 80 years, concomitant P‑glycoprotein inhibitors (all DOACs), and CYP3A4 inhibitors (rivaroxaban, apixaban, edoxaban) warrant a longer pre‑operative interruption【2】.
• Pre‑operative bridging with UFH or LMWH is NOT recommended for DOACs; bridging has been shown to increase bleeding without reducing thrombotic events【2】.
• Resume DOACs at least 6 hours after surgery once adequate hemostasis is confirmed【2】.
  
  • Twice‑daily regimens: resume the evening of the surgical day.
  • Once‑daily morning regimens: resume the next morning.
  • Once‑daily evening regimens: resume the same evening if ≥ 6 hours have elapsed【2】.
• If bleeding persists or surgery is contraindicated, delay DOAC resumption and use prophylactic anticoagulation instead【2】.
• Routine coagulation monitoring is unnecessary when recommended interruption periods are observed; monitoring is reserved for very high‑risk procedures or patients with drug‑accumulation risk factors【2】.

Antiplatelet Agent Management

• Clopidogrel or ticagrelor should be stopped 7–10 days before high‑bleeding‑risk surgery in patients without recent coronary events【3】.
• Bare‑metal coronary stents: avoid elective surgery within 6 weeks of placement【3】.
• Drug‑eluting coronary stents: avoid elective surgery within 6 months of placement【3】.
• When surgery cannot be delayed in stented patients, continue dual antiplatelet therapy despite the bleeding risk【3】.

Common Pitfalls to Avoid

• Never bridge DOACs with heparin; this markedly raises bleeding risk without providing thrombotic protection【2】.
• Avoid neuraxial anesthesia when residual DOAC levels may be present, especially in elderly or renally impaired patients【2】.
• Reserve warfarin bridging for only the highest thrombotic‑risk patients; routine bridging is discouraged【1】.
• Do not proceed with surgery if INR > 1.5 in patients on warfarin【1】.
• Do not overlook drug interactions (P‑glycoprotein or CYP3A4 inhibitors) that can prolong DOAC clearance【2】.
• Do not assume normal warfarin clearance in elderly patients; delayed decay may occur【3】.

Management of Anticoagulants Before Surgery

Introduction to Anticoagulant Management

• The American Society of Anesthesiologists recommends that discontinuation timing of anticoagulants before surgery should be based on the bleeding risk of the procedure, the type of anticoagulant, and patient-specific factors such as renal function 4, 5

Direct Oral Anticoagulants (DOACs)

• For patients on DOACs requiring low bleeding risk procedures, the European Society of Anaesthesiology recommends interrupting DOACs the night before the procedure regardless of the specific DOAC type 4, 5
• The American College of Cardiology recommends that for twice daily regimens, the last dose should be taken on the morning of the day before surgery, and for once daily morning regimens, the last dose should be on the morning of the day before surgery 6
• For once daily evening regimens, the last dose should be two days before surgery, as recommended by the American Heart Association 6
• Bridging with heparin is not recommended before procedures with low bleeding risk, according to the American College of Chest Physicians 6
• For rivaroxaban, apixaban, and edoxaban, the American Society of Regional Anesthesia and Pain Medicine recommends discontinue 3 days before the procedure 4, 7
• For dabigatran, the European Society of Cardiology recommends discontinue based on renal function: 4 days before if creatinine clearance >50 mL/min, and 5 days before if creatinine clearance 30-50 mL/min 4, 7, 8, 9

Vitamin K Antagonists (Warfarin)

• The European Society of Cardiology recommends stopping warfarin 3-5 days before surgery with daily INR monitoring until ≤1.5 is reached 10
• The American College of Cardiology recommends starting LMWH or UFH one day after discontinuation of warfarin or when INR <2.0, and considering postponing the procedure if INR >1.5 on the day of surgery 10

Resumption of Anticoagulation

• The American Society of Anesthesiologists recommends resuming DOACs at least 6 hours after the end of the procedure if adequate hemostasis is achieved, and considering delaying resumption if there is ongoing bleeding or surgical contraindication 6, 7
• The European Society of Cardiology recommends resuming warfarin 1-2 days after surgery depending on hemostatic status, using the pre-operative maintenance dose plus a 50% boosting dose for two consecutive days, and continuing LMWH or UFH until the INR returns to therapeutic levels 10

Special Considerations

• The American College of Chest Physicians recommends that no bridging with heparin is needed for DOACs except in very high thrombotic risk patients, and that recent evidence shows increased bleeding risk with bridging anticoagulation without reduction in thrombotic risk 4, 6, 9

Common Pitfalls to Avoid

• The European Society of Anaesthesiology recommends considering renal function when stopping dabigatran, avoiding unnecessary bridging with heparin for DOACs, ensuring adequate discontinuation time before neuraxial anesthesia, checking INR before procedures in patients on warfarin, and not resuming full-dose anticoagulation too early after surgery with high bleeding risk 4, 6, 7, 8, 10

Management of Apixaban for Dental Procedures

Protocol for Apixaban Management

• For higher bleeding risk dental procedures, consider a longer interruption period of 48 hours, as recommended by the American Society of Anesthesiologists 11, 12
• If unexpected heavy bleeding occurs during the procedure, delay resumption of apixaban until adequate hemostasis is achieved, according to the American College of Cardiology 11, 13
• Confirm adequate hemostasis before resuming apixaban, as suggested by the American Heart Association 11
• Resume the regular twice-daily dosing schedule starting with the evening dose on the day of the procedure, with a strength of evidence level of moderate, according to the American College of Chest Physicians 11
• If there are concerns about ongoing bleeding, postpone resumption and consider appropriate thromboprophylaxis if the patient is at high thrombotic risk, as recommended by the American College of Cardiology 11, 14

Perioperative Management of Direct Oral Anticoagulants (DOACs): Evidence‑Based Bleeding Risk Stratification and Anticoagulation Pitfalls

Procedure‑Related Bleeding Risk Stratification

• High‑bleeding‑risk surgeries (e.g., major abdominal or oncologic resections, hip/knee arthroplasty, cardiac, intracranial, spinal, urologic or gastrointestinal surgery with anastomosis, and any operation lasting > 45 minutes) are classified as high risk for peri‑operative bleeding and therefore require longer pre‑operative DOAC interruption. 15
• Neuraxial anesthesia (spinal or epidural techniques) is specifically designated as high‑risk because bleeding in the neuraxis can cause catastrophic neurologic injury. 15
• Low‑to‑moderate‑bleeding‑risk procedures such as arthroscopy, colonoscopy with biopsy, abdominal hernia repair, dental extractions of 1–3 teeth, cataract surgery, and implantation of pacemakers or ICDs are considered moderate risk and generally allow shorter DOAC hold periods. 15
• Minimal‑bleeding‑risk procedures (e.g., minor dermatologic interventions, routine dental cleanings, simple dental fillings) can often be performed without interrupting DOAC therapy. 15

Peri‑operative Anticoagulation Pitfalls

• Early postoperative low‑molecular‑weight heparin (LMWH) use (< 24 h after major surgery) before adequate hemostasis markedly increases major bleeding risk (≈ 20 % increase) and should be avoided; therapeutic DOACs should not be resumed until hemostasis is confirmed. 15